BACKGROUND: The global obesity epidemic has increased the prevalence of fatty liver disease. At present, 14% to 27% of the general population in the industrialized world has non-alcoholic fatty liver disease (NAFLD). METHOD: We review pertinent publications retrieved by a selective search of the PubMed database for the years 1995 to 2013. RESULTS: The term "non-alcoholic fatty liver disease" covers cases of a wide spectrum of severity, ranging from bland fatty liver without any inflammation and with little or no tendency to progress all the way to non-alcoholic steato-hepatitis (NASH) with inflammatory reactions and hepatocyte damage, with or without fibrosis. Some 5% to 20% of patients with NAFLD develop NASH, which undergoes a further transition to higher-grade fibrosis in 10% to 20% of cases. In fewer than 5% of cases, fibrosis progresses to cirrhosis. These approximate figures lead to an estimate of 0.05% to 0.3% for the prevalence of cirrhosis in the general population. About 2% of all cirrhosis patients per year develop hepatocellular carcinoma. The diagnosis of fatty liver disease can be suspected initially on the basis of abnormally high aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) levels and abnormal ultrasonographic findings. The positive predictive value of an ultrasonographic study for mild steatosis is 67% at most. The NAFLD fibrosis score, which is computed on the basis of multiple parameters (age, body-mass index, diabetes status, ASAT, ALAT, platelet count, and albumin level), has a positive predictive value of 82% to 90% and a negative predictive value of 88% to 93%. Liver biopsy is the gold standard for diagnosis but should be performed sparingly in view of its rare but sometimes life-threatening complications, such as hemorrhage. The treatment of NAFLD and NASH consists mainly of changes in lifestyle and nutrition. CONCLUSION: NAFLD can, in principle, be reversed. This is only possible with weight reduction by at least 3% to 5%.
BACKGROUND: The global obesity epidemic has increased the prevalence of fatty liver disease. At present, 14% to 27% of the general population in the industrialized world has non-alcoholic fatty liver disease (NAFLD). METHOD: We review pertinent publications retrieved by a selective search of the PubMed database for the years 1995 to 2013. RESULTS: The term "non-alcoholic fatty liver disease" covers cases of a wide spectrum of severity, ranging from bland fatty liver without any inflammation and with little or no tendency to progress all the way to non-alcoholic steato-hepatitis (NASH) with inflammatory reactions and hepatocyte damage, with or without fibrosis. Some 5% to 20% of patients with NAFLD develop NASH, which undergoes a further transition to higher-grade fibrosis in 10% to 20% of cases. In fewer than 5% of cases, fibrosis progresses to cirrhosis. These approximate figures lead to an estimate of 0.05% to 0.3% for the prevalence of cirrhosis in the general population. About 2% of all cirrhosispatients per year develop hepatocellular carcinoma. The diagnosis of fatty liver disease can be suspected initially on the basis of abnormally high aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) levels and abnormal ultrasonographic findings. The positive predictive value of an ultrasonographic study for mild steatosis is 67% at most. The NAFLD fibrosis score, which is computed on the basis of multiple parameters (age, body-mass index, diabetes status, ASAT, ALAT, platelet count, and albumin level), has a positive predictive value of 82% to 90% and a negative predictive value of 88% to 93%. Liver biopsy is the gold standard for diagnosis but should be performed sparingly in view of its rare but sometimes life-threatening complications, such as hemorrhage. The treatment of NAFLD and NASH consists mainly of changes in lifestyle and nutrition. CONCLUSION: NAFLD can, in principle, be reversed. This is only possible with weight reduction by at least 3% to 5%.
Authors: Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: A Marcos; R A Fisher; J M Ham; A T Olzinski; M L Shiffman; A J Sanyal; V A Luketic; R K Sterling; M E Olbrisch; M P Posner Journal: Transplantation Date: 2000-06-15 Impact factor: 4.939
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch Journal: Dtsch Arztebl Int Date: 2017-08-07 Impact factor: 5.594
Authors: Ahmad Moolla; Kenzo Motohashi; Thomas Marjot; Amelia Shard; Mark Ainsworth; Alastair Gray; Rury Holman; Michael Pavlides; John D Ryan; Jeremy W Tomlinson; Jeremy F Cobbold Journal: Frontline Gastroenterol Date: 2019-04-30
Authors: Christoph Mahlke; Diego Hernando; Christina Jahn; Antonio Cigliano; Till Ittermann; Anne Mössler; Marie-Luise Kromrey; Grazyna Domaska; Scott B Reeder; Jens-Peter Kühn Journal: J Magn Reson Imaging Date: 2016-05-19 Impact factor: 4.813